Wall Street analysts forecast that BioScrip Inc (NASDAQ:BIOS) will post $177.51 million in sales for the current fiscal quarter, Zacks reports. Two analysts have made estimates for BioScrip’s earnings. The lowest sales estimate is $177.01 million and the highest is $178.00 million. BioScrip reported sales of $168.58 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 5.3%. The company is expected to report its next quarterly earnings report on Thursday, May 9th.
According to Zacks, analysts expect that BioScrip will report full year sales of $754.46 million for the current year, with estimates ranging from $750.72 million to $761.65 million. For the next fiscal year, analysts forecast that the business will post sales of $800.52 million, with estimates ranging from $794.00 million to $807.03 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that cover BioScrip.
BioScrip (NASDAQ:BIOS) last issued its quarterly earnings data on Friday, March 15th. The company reported ($0.14) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.03) by ($0.11). The business had revenue of $183.57 million for the quarter, compared to analyst estimates of $188.39 million. During the same period in the previous year, the business earned ($0.03) EPS. BioScrip’s revenue for the quarter was up .5% compared to the same quarter last year.
BioScrip stock traded down $0.01 during mid-day trading on Friday, reaching $1.76. 39,119 shares of the company traded hands, compared to its average volume of 2,054,197. BioScrip has a fifty-two week low of $1.69 and a fifty-two week high of $4.14. The firm has a market capitalization of $225.54 million, a price-to-earnings ratio of -3.58 and a beta of 0.69.
Hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. lifted its stake in BioScrip by 28.8% in the fourth quarter. BlackRock Inc. now owns 9,807,734 shares of the company’s stock valued at $35,013,000 after buying an additional 2,191,490 shares during the last quarter. Vanguard Group Inc lifted its position in shares of BioScrip by 0.5% during the 3rd quarter. Vanguard Group Inc now owns 5,987,679 shares of the company’s stock worth $18,562,000 after buying an additional 27,904 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of BioScrip by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 5,987,679 shares of the company’s stock worth $18,562,000 after buying an additional 27,904 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of BioScrip by 7.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,617,021 shares of the company’s stock worth $9,342,000 after buying an additional 180,389 shares during the last quarter. Finally, Rothschild & Co. Asset Management US Inc. lifted its position in shares of BioScrip by 4.3% during the 4th quarter. Rothschild & Co. Asset Management US Inc. now owns 2,267,421 shares of the company’s stock worth $8,095,000 after buying an additional 92,595 shares during the last quarter. 82.40% of the stock is owned by institutional investors and hedge funds.
BioScrip Company Profile
BioScrip, Inc provides infusion and home care management solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.